These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 14695237)

  • 1. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.
    Gopal AK; Pagel JM; Hedin N; Press OW
    Blood; 2004 May; 103(9):3516-20. PubMed ID: 14695237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
    Shan D; Gopal AK; Press OW
    Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
    Cowan AJ; Stevenson PA; Gooley TA; Frayo SL; Oliveira GR; Smith SD; Green DJ; Roden JE; Pagel JM; Wood BL; Press OW; Gopal AK
    Br J Haematol; 2017 Feb; 176(4):583-590. PubMed ID: 28055107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different ways to induce apoptosis by fenretinide and all-trans-retinoic acid in human B lymphoma cells.
    Barna G; Sebestyén A; Weischede S; Peták I; Mihalik R; Formelli F; Kopper L
    Anticancer Res; 2005; 25(6B):4179-85. PubMed ID: 16309214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
    Daniel D; Yang B; Lawrence DA; Totpal K; Balter I; Lee WP; Gogineni A; Cole MJ; Yee SF; Ross S; Ashkenazi A
    Blood; 2007 Dec; 110(12):4037-46. PubMed ID: 17724141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
    Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
    Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
    Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity.
    Formelli F; Cleris L
    Cancer Res; 1993 Nov; 53(22):5374-6. PubMed ID: 8221674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells.
    You KR; Shin MN; Park RK; Lee SO; Kim DG
    Hepatology; 2001 Dec; 34(6):1119-27. PubMed ID: 11732001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of N-(4-hydroxyphenyl)retinamide-induced apoptosis in breast cancer cells by galectin-3.
    Choi JH; Chun KH; Raz A; Lotan R
    Cancer Biol Ther; 2004 May; 3(5):447-52. PubMed ID: 15326375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
    Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation.
    Appierto V; Tiberio P; Villani MG; Cavadini E; Formelli F
    Carcinogenesis; 2009 May; 30(5):824-31. PubMed ID: 19325135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.
    Suzuki S; Higuchi M; Proske RJ; Oridate N; Hong WK; Lotan R
    Oncogene; 1999 Nov; 18(46):6380-7. PubMed ID: 10597238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines.
    Cuello M; Coats AO; Darko I; Ettenberg SA; Gardner GJ; Nau MM; Liu JR; Birrer MJ; Lipkowitz S
    Cell Death Differ; 2004 May; 11(5):527-41. PubMed ID: 14765134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
    Xuan C; Steward KK; Timmerman JM; Morrison SL
    Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo.
    Wang M; Han XH; Zhang L; Yang J; Qian JF; Shi YK; Kwak LW; Romaguera J; Yi Q
    Leukemia; 2008 Jan; 22(1):179-85. PubMed ID: 17898787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
    Zhang N; Khawli LA; Hu P; Epstein AL
    Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells.
    Kim HJ; Chakravarti N; Oridate N; Choe C; Claret FX; Lotan R
    Oncogene; 2006 May; 25(19):2785-94. PubMed ID: 16407847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(L-glutamic acid) against ovarian cancer xenografts.
    Zou C; Brewer M; Cao X; Zang R; Lin J; Deng Y; Li C
    Gynecol Oncol; 2007 Dec; 107(3):441-9. PubMed ID: 17854871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.